Similar articles

• Quinidine concentration in serum. The stability during maintained treatment with two different types of delayed absorption tablets.

  Ditlefsen EM, Bjerkelund C. Ditlefsen EM, et al. Acta Med Scand. 1966 Nov;180(5):537-42. Acta Med Scand. 1966. PMID: 5923373 Clinical Trial. No abstract available.
• Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.

  Frigo GM, Perucca E, Teggia-Droghi M, Gatti G, Mussini A, Salerno J. Frigo GM, et al. Br J Clin Pharmacol. 1977 Aug;4(4):449-54. doi: 10.1111/j.1365-2125.1977.tb00760.x. Br J Clin Pharmacol. 1977. PMID: 901736 Free PMC article.
• Serum quinidine levels after administration of three different quinidine preparations.

  Henning R, Nyberg G. Henning R, et al. Eur J Clin Pharmacol. 1973 Dec;6(4):239-44. doi: 10.1007/BF00644739. Eur J Clin Pharmacol. 1973. PMID: 4591150 Clinical Trial. No abstract available.
• Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.

  Zinny MA, Taggart WV. Zinny MA, et al. Clin Ther. 1984;7(1):22-7. Clin Ther. 1984. PMID: 6518461 Clinical Trial.
• Quinidine dosage, with special reference to an oral loading dose schedule.

  Collste P, Nordlander R. Collste P, et al. Br J Clin Pharmacol. 1979 Mar;7(3):293-7. doi: 10.1111/j.1365-2125.1979.tb00935.x. Br J Clin Pharmacol. 1979. PMID: 427006 Free PMC article.